You searched for "disease"

590 results found

Active surveillance for small renal masses in younger patients

Active surveillance (AS) is discussed as an option for renal masses <2cm in patients with significant competing risks for mortality. This multicentre data from the US seeks to fill an important gap in current guidelines for provision of this option...

Factors and time to conversion from prostate cancer active surveillance to treatment

Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...

Cortical stimulation for voiding dysfunction in multiple sclerosis

Voiding dysfunction (VD) increases morbidity in patients with multiple sclerosis (MS), and may be associated with urinary tract infections, stones and renal failure. Catheterisation is required when impaired hand function precludes self-catheterisation, which is associated with further morbidity. In this...

PIRADS-3 lesions and clinically significant prostate cancer – what are we missing?

The use of pre-biopsy MRI has definitely enhanced our decision making in managing patients with suspected prostate cancer (PCa). There is still uncertainty around the outcomes for patients with PIRADS-3 lesions, with a small but definite risk of missing clinically...

Urethral stenosis after radiation therapy for prostate cancer

One of the most common causes of bladder outflow obstruction in post radiotherapy (RT) cases is urethral stenosis. These cases are miserable and moribund with poor flow rates, incomplete bladder emptying, recurrent urinary tract infections and haematuria. The reported incidence...

Prostate Cancer UK warns of over 8,600 ‘missing men’ as referrals drop by 52,000

The Covid-19 pandemic has led to around 52,000 (28%) fewer urgent prostate cancer referrals in England alone, according to statistics shared by Prostate Cancer UK. It’s estimated that more than 8,600 fewer men started treatment for...

Bupa covers accurate PSE prostate cancer blood test

A new era in prostate cancer detection is emerging with the EpiSwitch® PSE blood test, a highly accurate tool that enhances early diagnosis while significantly cutting false positives. Now covered by Bupa as a pre-biopsy test, PSE has demonstrated 94%...

BAUS Annual Meeting 2024

Welcome from the Honorary Secretary I am thrilled to extend a warm welcome to each and every one of you as we gear up for what promises to be an enriching and enlightening conference experience. On behalf of Mo Belal,...

Understanding Stauffer’s syndrome

Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...

Introduction to prostate cryotherapy

Introduction Cryotherapy was first described by Dr James Arnott in 1850 where he used crushed ice and salt to get temperatures as low as -24oC, in the treatment of cervical and breast tumours [1]. The literature on prostatic cryotherapy dates...

Management of stage 1 non-seminomatous germ cell tumours

Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

Prostate cancer: Black men more likely to be diagnosed at later stages

Latest data shows Black men have higher rates of stage 3 or stage 4 prostate cancer diagnoses compared with white men. Black men diagnosed at a later stage in their 60s are 14% less likely to get NICE approved treatment...